Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Speciality: Rheumatology
Description:
A warm welcome to all the medical professionals in this case-based panel discussion on the role of CDK 4/6 inhibitors in clinical practice.
Cyclin-dependent kinase (CDK) 4/6 inhibitors are a class of anticancer medications. It is also helpful in reducing or eliminating endocrine resistance when used in combination with endocrine therapy. It can be used for the treatment of hormone receptor–positive (HR+) breast cancer.
The CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib are observed to enhance the change in the treatment paradigm for patients with HR+/HER2− advanced breast cancer. Moreover, these drugs have demonstrated a meaningful improvement in PFS when used for first- or later-line therapy.
Therefore, listen to the webinar, grab the knowledge that is shared, and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Hydroxyurea Shows Some Benefits in Milder Sickle Cell Disease
2.
Research uncovers hidden Australian skin cancer epidemic
3.
Immunotherapy and targeted radiation shrink liver tumors, enabling surgery
4.
In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.
5.
The American College of Physicians updated its recommendations for colorectal cancer screening.
1.
Understanding Carcinoid Tumors: Diagnosis, Symptoms, and Treatment Options
2.
The Role of Alanine Aminotransferase in Liver Health and Disease
3.
Unveiling Canine Blood Clots Over Time: A Look at Low-Field MRI's Diagnostic Potential
4.
Breaking Down the Different Types of Lymphoma: What You Need to Know
5.
Pharmacological Frontier of Precision Oncology, Immunotherapies, and the Evolving Art of Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
2.
Efficient Management of First line ALK-rearranged NSCLC - Part V
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
4.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge